Researchers may have found a solution to treating a bone marrow cancer proven to be resistant to several standard therapies.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.
Shares of U.K.-based NuCana were down more than 21 percent after the company announced suspended enrollment of patients in a late-stage pancreatic cancer study.
Teva Pharmaceutical Industries Ltd.’s anti-CGRP drug fremanezumab hit the target reducing monthly migraine days in a late-stage study.
A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations
AstraZeneca made strides toward the company’s goal of adding heart failure to the conditions that can be treated by Farxiga, putting the diabetes drug ahead of a rival medicine from Eli Lilly.
Regeneron Pharmaceuticals announced positive results from the company’s pivotal Phase III clinical trial of evinacumab in homozygous familial hypercholesterolemia (HoFH).
Eli Lilly announced that the company’s psoriasis drug Taltz overcame Johnson & Johnson’s Tremfya in a head-to-head study.
Regeneron Pharmaceuticals Inc. said the company’s experimental treatment for Ebola proved superior to a rival therapy from Mapp Biopharmaceutical at preventing death.
AstraZeneca Plc said a late-stage study showed the company’s top-selling drug Tagrisso had significantly helped patients with a type of lung cancer live longer without the disease worsening.